Saflutan

/ Rafa

The recommended dose is one drop of SAFLUTAN in the conjunctival sac of the
affected eye(s) once daily in the evening.
The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect.
For single use only, one container is sufficient to treat both eyes. Any unused
solution should be discarded immediately after use.
Use in elderly: No dosage alteration in elderly patients is necessary.
Paediatric population: The safety and efficacy of tafluprost in children below age 18 has not yet been established. No data are available.
Use in renal/hepatic impairment: Tafluprost has not been studied in patients with renal/hepatic impairment and should therefore be used with caution in such patients.
Method of administration: To reduce the risk of darkening of the eyelid skin the patients should wipe off any excess solution from the skin. As with any other eye drops, nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route.
If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. As monotherapy in patients: Who would benefit from preservative free eye drops; insufficiently responsive to first line therapy; intolerant or contra-indicated to first line therapy.As adjunctive therapy to beta-blockers.

Hypersensitivity to tafluprost or to any of the excipients.

Before treatment, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular edema or iritis/uveitis. Patients with severe asthma should be treated with caution.Pregnancy and lactation: Must not be used in women of childbearing age/potential unless adequate contraceptive measures are in place. Should not be used during pregnancy unless clearly necessary. Should not be used during breast-feeding.

Very common: Conjunctival/ocular hyperemia.
See prescribing information for full details.

No interactions are anticipated since systemic concentrations are extremely low following ocular dosing.